Effect of nuclear factor-κB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis

Journal of Rheumatology

Volumn 32, Issue 8, 2005, Pages 1440-1447

  Okazaki, Yuko ^a   Sawada, Tetsuji ^a   Nagatani, Katsuya ^a   Komagata, Yoshinori ^a   Inoue, Tetsufumi ^b   Muto, Susumu ^c   Itai, Akiko ^d   Yamamoto, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO UNIVERSITY OF FOREIGN STUDIES   (Japan)

^c Drug Discovery Department   (Spain)

^d Institute of Molecular Design Inc

Author keywords

Collagen induced arthritis; Fibroblast like synoviocytes; Nuclear factor B; Rheumatoid arthritis

Indexed keywords

BENZAMIDE DERIVATIVE; CYTOKINE; I KAPPA B KINASE; IMD 0560; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; N 2,5 BIS(TRIFLUOROMETHYLPHENYL) 5 BROMO 2 HYDROXYBENZAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BENZAMIDES; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; I-KAPPA B PROTEINS; KIDNEY; MALE; MICE; MICE, INBRED DBA; NF-KAPPA B; PHOSPHORYLATION; SYNOVIAL MEMBRANE;

EID: 23444438720     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappa B in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
2. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
3. Firestein GS. Invasive frbroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-90.
4. Tak PP, Firestein GS. NF-kappa B: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
5. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
6. Firestein GS, Manning AM. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999;42:609-21.
7. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
8. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 2000;18:621-63.
9. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
10. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
11. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa) B kinase-beta. Nature 1998;396:77-80.
12. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000;164:5981-9.
13. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74.
14. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappa B activation through inhibition of I kappa B alpha phosphorylation and degradation. J Immunol 2001;167:2911-20.
15. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165:5962-9.
16. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999;42:2532-42.
17. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappa B kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-907.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
19. Kurokouchi K, Jacobs CR, Donahue HJ. Oscillating fluid flow inhibits TNF-alpha-induced NF-kappa B activation via an I kappa B kinase pathway in osteoblast-like UMR106 cells. J Biol Chem 2001;276:13499-504.
20. Hietala MA, Jonsson IM, Tarkowski A, Kleinau S, Pekna M. Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol 2002;169:454-9.
21. Krishan A, Parka K, Frei E III. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, YP-16-213) on the cell cycle traverse of human lymphoblasts. J Cell Biol 1975;66:521-30.
22. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8.
23. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003;15:15-21.
24. Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not OEBP beta or c-Jun. J Immunol 2000;165:7199-206.
25. Martin T, Cardarelli PM, Parry GC, Felts KA, Cobb RR. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-kappa B and AP-1. Eur J Immunol 1997;27:1091-7.
26. Gerlag DM, Ransone L, Tak PP, et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000;165:1652-8.
27. Cuzzocrea S, Chatterjee PK, Mazzon E, et al. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol 2002;135:496-510.
28. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
29. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24.
30. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappa B activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95:13859-64.
31. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappa B and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001;12:73-90.
32. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.